Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What is the mechanism of action of aprepitant?

NK 1 receptor antagonist. ***NK 1 receptor antagonist*** - Aprepitant selectively blocks the **neurokinin-1 (NK1) receptor**, which is activated by **substance P**. - This mechanism is effective in preventing both acute and delayed **chemotherapy-induced nausea and vomiting (CINV)** by inhibiting the CNS vomiting reflex. *RANK ligand inhibitor* - **RANK ligand inhibitors** such as **denosumab** target bone resorption in conditions like osteoporosis and bone metastases. - This mechanism is not related to the antiemetic properties of aprepitant. *NMDA antagonist* - **NMDA receptor antagonists** like **ketamine** are primarily used for their anesthetic or analgesic effects. - They work by blocking the N-methyl-D-aspartate receptor, which is distinct from the NK1 receptor. *5-HT3 antagonist* - **5-HT3 antagonists** like **ondansetron** block serotonin receptors, primarily in the gastrointestinal tract and chemoreceptor trigger zone. - While also antiemetics, their mechanism is different from aprepitant, and they are often used in combination for CINV.

Q: Which of the following drugs is LEAST likely to be delivered via a liposome drug delivery system?

Hyoscine. ***Hyoscine*** - **Hyoscine** (scopolamine) is a **small, lipid-soluble anticholinergic molecule** that readily crosses cell membranes and the blood-brain barrier due to its high **lipophilicity**. - Its excellent **oral and transdermal bioavailability** and ability to reach target tissues without assistance make liposomal encapsulation unnecessary and clinically redundant. - Unlike the other drugs listed, hyoscine does **not suffer from dose-limiting toxicity** that would benefit from targeted delivery. *Amphotericin B* - **Amphotericin B** is a potent **antifungal agent** with severe dose-limiting **nephrotoxicity** and infusion-related reactions. - **Liposomal formulations (AmBisome®)** are FDA-approved and widely used to significantly **reduce nephrotoxicity** while maintaining antifungal efficacy. - The liposomal delivery alters tissue distribution, reducing kidney exposure while enhancing accumulation in target tissues. *Vincristine* - **Vincristine** is a **vinca alkaloid chemotherapy agent** with dose-limiting **neurotoxicity** and poor tumor penetration. - **Liposomal vincristine (Marqibo®)** is FDA-approved and provides **prolonged circulation time**, enhanced tumor delivery, and reduced neurotoxicity. - The encapsulation improves the therapeutic index by increasing drug concentration at tumor sites. *Amikacin* - **Amikacin** is an **aminoglycoside antibiotic** with significant **nephrotoxicity and ototoxicity** that limit systemic dosing. - **Liposomal amikacin (Arikayce®)** is FDA-approved for mycobacterial lung infections, allowing **targeted pulmonary delivery** with reduced systemic exposure. - The formulation enables higher local drug concentrations with improved safety profile.

Q: What is the role of oxidation in biotransformation?

Functionalization reaction. ***Functionalization reaction*** - Oxidation is a **Phase I biotransformation reaction**, which primarily involves introducing or exposing a functional group (like hydroxyl, carboxyl, amine) on the parent compound. - This makes the molecule more **polar** and often more reactive, preparing it for subsequent Phase II (conjugation) reactions. *Conjugation reaction* - Conjugation reactions are **Phase II biotransformation reactions**, which involve the covalent attachment of a large, highly polar, endogenous molecule (e.g., glucuronic acid, sulfate, glutathione) to the functional group created during Phase I. - Their main role is to further increase **water solubility** and facilitate **excretion**, rather than introducing functional groups. *Synthetic reaction* - The term "synthetic reaction" is a general chemical term and not a specific, commonly used classification for biotransformation phases in pharmacology. - While biotransformation involves chemical synthesis within the body, this term does not accurately describe the specific role of oxidation in drug metabolism. *Felson reaction* - The "Felson reaction" is **not a recognized term** in the context of biotransformation or drug metabolism. - This option is a distracter and does not correspond to any known biochemical process.

Q: What is the mechanism of elimination for Atracurium?

Nonenzymatic degradation. ***Nonenzymatic degradation*** - Atracurium is primarily metabolized via **Hofmann elimination**, a **nonenzymatic chemical degradation** process that occurs at physiological pH and temperature, and **ester hydrolysis** by plasma esterases. - This mechanism is advantageous in patients with **renal or hepatic impairment** as its elimination is independent of these organ systems. *Renal excretion* - While some metabolites of atracurium are renally excreted, **renal excretion is not the primary mechanism** of its initial breakdown or elimination. - Drugs primarily eliminated by renal excretion would require dose adjustments in patients with **kidney disease**. *Hepatic elimination* - Atracurium does not depend on the liver for its primary metabolism, making it a suitable choice for patients with **hepatic dysfunction**. - Medications primarily undergoing hepatic elimination, often via **cytochrome P450 enzymes**, would be significantly affected by liver health. *None of the above* - This option is incorrect because nonenzymatic degradation (Hofmann elimination and ester hydrolysis) is a well-established and unique mechanism for atracurium's excretion. - The drug's mechanism of action and metabolism are clearly defined in pharmacology.

Q: Which of the following statements about oxcarbazepine is incorrect?

Less chances of hyponatremia than carbamazepine. ***Correct Answer: Less chances of hyponatremia than carbamazepine*** - This statement is **incorrect** because oxcarbazepine has a **higher incidence of hyponatremia** (up to 25% of patients) compared to carbamazepine (5-10%). - Hyponatremia is a well-known and dose-related adverse effect of oxcarbazepine, often requiring monitoring of serum sodium levels. - This is the most definitively incorrect statement among the options. *Incorrect: Metabolises itself* - While this statement is somewhat ambiguous, it likely refers to **autoinduction of metabolism**, which is a characteristic of **carbamazepine** [1]. - **Oxcarbazepine** is a prodrug that is rapidly converted to its active metabolite monohydroxy derivative (MHD), but it **does not autoinduce its own metabolism** to a significant extent like carbamazepine does [1]. - However, if interpreted literally, oxcarbazepine does undergo metabolism, making this statement potentially confusing. *Incorrect: Less chances of hepatotoxicity than carbamazepine* - This statement is **correct** about oxcarbazepine. It is generally associated with a **lower risk of severe hepatotoxicity** [1] compared to carbamazepine. - While liver enzyme elevations can occur, serious liver damage is much less common with oxcarbazepine. *Incorrect: It is less enzyme inducer than carbamazepine* - This statement is **correct** about oxcarbazepine. Its active metabolite MHD is a **weaker inducer of cytochrome P450 enzymes** (especially CYP3A4) than carbamazepine. - This translates to fewer and less significant drug-drug interactions with oxcarbazepine.

Q: Most variable absorption is seen with which route?

Oral. ***Oral*** - **Oral absorption** is highly variable due to numerous factors, including stomach pH, presence of food, drug formulation, and individual patient differences in gastrointestinal motility and enzyme activity [1], [3]. - The drug must first dissolve and then pass through the **intestinal wall** into the bloodstream, where it is also subject to **first-pass metabolism** in the liver, all contributing to variability [2]. *Intramuscular* - While generally reliable, **intramuscular absorption** can vary depending on factors such as muscle blood flow, which can be influenced by activity, temperature, and depth of injection. - However, it bypasses the harsh gastrointestinal environment and has less intrinsic variability than oral administration. *Intravenous* - **Intravenous administration** provides the most direct and complete absorption, as the drug is introduced directly into the bloodstream, bypassing all absorption barriers. - Therefore, it exhibits **no variability in absorption** (bioavailability is 100%), making this option incorrect [4]. *Per rectal* - **Rectal absorption** can be variable, as it depends on factors like the drug's lipid solubility, the pH of the rectal fluid, and the presence of fecal matter. - However, it typically avoids **first-pass metabolism** to some extent and often provides more predictable absorption than oral routes, especially for drugs irritating to the stomach.

Q: Depot preparations are administered by ?

Both subcutaneous and intramuscular route. ***Both subcutaneous and intramuscular route*** - **Depot preparations** are designed for **sustained release** of medication over an extended period - This is achieved by forming a 'depot' in the tissue, often facilitated by a viscous vehicle or sparingly soluble form of the drug - Both **subcutaneous** and **intramuscular** tissues can sustain depot formulations effectively - **SC depot examples:** Insulin glargine, contraceptive implants (Nexplanon), leuprolide acetate - **IM depot examples:** Haloperidol decanoate, medroxyprogesterone acetate (Depo-Provera), paliperidone palmitate, long-acting risperidone *Subcutaneous route* - While some **depot preparations** are administered **subcutaneously**, it is not the *only* route for all depot formulations - The **subcutaneous tissue** offers relatively low blood flow, suitable for slow absorption - Alone, this option is incomplete as many depot preparations require IM administration *Intramuscular route* - Many **depot preparations** are given **intramuscularly** due to the muscle tissue's vascularity and tissue volume - The **muscle tissue** provides an excellent site for drug reservoir formation - Alone, this option is incomplete as some depot preparations are given subcutaneously *Intravenous route* - **Intravenous administration** is used for immediate and rapid drug delivery directly into the bloodstream - This route is **unsuitable for depot preparations** which require sustained release over time - No 'depot' can be formed with IV route as the drug is immediately diluted and distributed throughout the body

Q: Which of the following is NOT an advantage of sustained release preparations over conventional preparations?

Drugs with very long half-life are suitable. ***Drugs with very long half-life are suitable*** - Sustained-release preparations are most suitable for drugs with a **half-life between 2 to 8 hours** (some sources suggest 3-12 hours). - Drugs with a **very long half-life (>12-24 hours)** are already long-acting enough that a sustained-release formulation offers **little to no additional benefit**. - Such drugs already maintain therapeutic levels for extended periods without the need for special formulation. - Formulating a drug with a very long half-life into a sustained-release form could lead to **excessive accumulation** and make dose adjustments difficult. - Therefore, suitability of drugs with very long half-life is **NOT an advantage** - it's actually a limitation of sustained-release technology. *Decreased frequency of administration* - This is a primary advantage of sustained release, as it allows for **less frequent dosing intervals** (e.g., once or twice daily instead of multiple times a day). - Reduced dosing frequency helps maintain **therapeutic drug levels** over a longer period without repeated administration. *Improved compliance* - Less frequent dosing directly contributes to **better patient adherence** to the medication regimen. - Patients are more likely to take their medication as prescribed when the **dosing schedule is simpler and less demanding**. *Less incidence of high peak side effects* - Sustained-release formulations provide a **slow and continuous drug release**, avoiding the rapid absorption and high plasma peaks seen with conventional formulations. - This smoother plasma concentration profile leads to **fewer dose-related side effects** associated with high peak drug concentrations.

Q: Which of the following is the longest acting oral anticoagulant?

Bishydroxycoumarin. ***Bishydroxycoumarin*** - **Bishydroxycoumarin** (dicoumarol) has a very long duration of action, with effects lasting up to 2-10 days after a single dose due to its slow metabolism and excretion. - Its prolonged action and unpredictable anticoagulant response have led to it being largely replaced by other oral anticoagulants like **warfarin** in clinical practice. *Warfarin* - **Warfarin** has a half-life of approximately 36-42 hours, leading to an anticoagulant effect that lasts for about 2-5 days after discontinuation. - It is a widely used oral anticoagulant, but its duration of action is significantly shorter than that of bishydroxycoumarin. *Acenocoumarol* - **Acenocoumarol** has a relatively short half-life of about 8-11 hours, and its anticoagulant effects typically dissipate within 1-2 days after discontinuation. - It is often preferred in situations where a rapid reversal of anticoagulation might be necessary, due to its shorter duration of action compared to warfarin. *Phenindione* - **Phenindione** is an indandione derivative, a class of oral anticoagulants, with a duration of action of approximately 2-4 days. - It is rarely used now due to a higher incidence of adverse effects, including hypersensitivity reactions and hematological toxicities, compared to coumarin derivatives.

Q: A young child weighing 20 kg is administered a drug at a dose of 100 mg/kg body weight. Given that the plasma concentration of the drug is 2 mg/dL and the clearance is 13,860 mL/hr, calculate the time required to reach steady state plasma concentration.

30 hours. ***30 hours*** - To reach **steady-state concentration**, approximately **5 half-lives (t½)** are required, at which point the drug reaches ~97% of steady state. - First, calculate the **volume of distribution (Vd)**: Total dose = 100 mg/kg × 20 kg = 2000 mg. Plasma concentration = 2 mg/dL = 20 mg/L. Therefore, **Vd = Dose/Cp = 2000 mg / 20 mg/L = 100 L**. - Next, calculate the **half-life (t½)** using the formula: **t½ = 0.693 × Vd / Cl**. Given **Clearance (Cl)** = 13,860 mL/hr = 13.86 L/hr, we get **t½ = (0.693 × 100 L) / 13.86 L/hr = 5 hours**. - Time to reach steady state = **5 × t½ = 5 × 5 hours = 25 hours**. While the calculated value is 25 hours, **30 hours (6 half-lives)** is the closest option and ensures steady state is definitively reached, as clinical practice often considers 4-6 half-lives as the range for steady state. *20 hours* - This duration represents only **4 half-lives**, which achieves approximately **94% of steady-state** concentration. - While close, this is slightly **premature** compared to the standard 5 half-lives required for steady state, and is further from the calculated 25 hours than the correct answer. *10 hours* - This duration represents only **2 half-lives**, which is **insufficient to reach steady-state** plasma concentration. - At 10 hours, the drug concentration would only be around **75% of steady-state**, not fully accumulated. *40 hours* - This duration represents **8 half-lives**, which is **excessively long** for achieving steady-state. - By this point, the drug would have been at **steady-state for several half-lives**, making this an unnecessarily prolonged estimate.

Question 1

What is the mechanism of action of aprepitant?

Accepted Answer

NK 1 receptor antagonist

Answer

RANK ligand inhibitor

Answer

NMDA antagonist

Answer

5-HT3 antagonist

Question 2

Which of the following drugs is LEAST likely to be delivered via a liposome drug delivery system?

Accepted Answer

Hyoscine

Answer

Amphotericin B

Answer

Vincristine

Answer

Amikacin

Question 3

What is the role of oxidation in biotransformation?

Accepted Answer

Functionalization reaction

Answer

Conjugation reaction

Answer

Synthetic reaction

Answer

Felson reaction

Question 4

What is the mechanism of elimination for Atracurium?

Accepted Answer

Nonenzymatic degradation

Answer

Renal excretion

Answer

Hepatic elimination

Answer

None of the above

Question 5

Which of the following statements about oxcarbazepine is incorrect?

Accepted Answer

Less chances of hyponatremia than carbamazepine

Answer

Metabolises itself

Answer

Less chances of hepatotoxicity than carbamazepine

Answer

It is less enzyme inducer than carbamazepine

Question 6

Most variable absorption is seen with which route?

Accepted Answer

Oral

Answer

Intravenous

Answer

Per rectal

Answer

Intramuscular

Question 7

Depot preparations are administered by ?

Accepted Answer

Both subcutaneous and intramuscular route

Answer

Subcutaneous route

Answer

Intravenous route

Answer

Intramuscular route

Question 8

Which of the following is NOT an advantage of sustained release preparations over conventional preparations?

Accepted Answer

Drugs with very long half-life are suitable

Answer

Improved compliance

Answer

Less incidence of high peak side effects

Answer

Decreased frequency of administration

Question 9

Which of the following is the longest acting oral anticoagulant?

Accepted Answer

Bishydroxycoumarin

Answer

Warfarin

Answer

Acenocoumarol

Answer

Phenindione

Question 10

A young child weighing 20 kg is administered a drug at a dose of 100 mg/kg body weight. Given that the plasma concentration of the drug is 2 mg/dL and the clearance is 13,860 mL/hr, calculate the time required to reach steady state plasma concentration.

Accepted Answer

30 hours

Answer

20 hours

Answer

10 hours

Answer

40 hours

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?